COMMUNIQUÉS West-GlobeNewswire

Equillium Reports First Quarter 2019 Financial Results and Recent Highlights
13/05/2019
EQUATE Phase 1b/2 trial in acute graft-versus-host disease (aGVHD) ongoing with data expected in 1Q 2020 On track to initiate Phase 1b proof-of-concept trials of itolizumab (EQ001) in uncontrolled asthma and lupus [...]
NextCure Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
13/05/2019
BELTSVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer [...]
ImmuCell Announces Unaudited Financial Results for First Quarter of 2019
13/05/2019
PORTLAND, Maine, May 13, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and [...]
CorMedix Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
13/05/2019
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and [...]
aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update
13/05/2019
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host conference call and [...]
TCR2 Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
13/05/2019
Initiated Phase 1/2 clinical trial for TC-210, TCR 2 ’s lead product candidate targeting mesothelin expressing solid tumors On track to file an IND for TCR 2 ’s lead hematology product candidate, TC-110, in patients [...]
Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights
13/05/2019
-- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in r/r NHL to be Presented at EHA and ICML in June -- – Updated Data from Phase 1b Trial of 5F9 as Monotherapy and in Combination with [...]
Molecular Templates, Inc. Reports First Quarter 2019 Financial Results
13/05/2019
AUSTIN, Texas, May 13, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s [...]
BioSyent Announces Health Canada Approval of New Women’s Health Product
13/05/2019
TORONTO, May 13, 2019 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Tibella ® (tibolone), indicated for the short-term treatment of vasomotor [...]
Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
13/05/2019
On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 13, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a [...]
ERYTECH Announces FDA’s Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States
13/05/2019
Investigational New Drug Application reviewed and accepted Enrollment of US patients expected to begin in Q3 2019 Clinical trial authorizations now obtained in all twelve participating countries LYON, France and [...]
ERYTECH annonce l'autorisation de la FDA américaine pour lancer l'étude de phase 3 avec eryaspase dans le cancer du pancréas aux États-Unis
13/05/2019
Demande d’ Investigational New Drug (IND) examinée et acceptée Début du recrutement de patients aux États-Unis prévu pour le troisième trimestre 2019 Obtention de l'autorisation de mener l’étude clinique désormais dans [...]
SPINEWAY : Réduction du capital social de Spineway
13/05/2019
Réduction du capital social de Spineway Erratum, annule et remplace le communiqué de presse du 7 mai Par décisions en date du 15 avril 2019, le Conseil d’Administration agissant sur délégation de compétence votée par l’ [...]
Precision Therapeutics to Report First Quarter 2019 Financial Results and Provide Company Update on Wednesday, May 15, 2019
13/05/2019
Conference Call to be held May 15, 2019, at 4:30pm Eastern Time MINNEAPOLIS, May 13, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces that it will report [...]
Kiadis Pharma Notice of Annual General Meeting of Shareholders
13/05/2019
Amsterdam, The Netherlands, 13 May 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company, today announces that its Annual [...]
N.M. Medical Cannabis First Quarter Patient Sales Up 16% Over 2018
13/05/2019
Enrollment gains dramatically outpace sales indicating illicit market activity, public health risks ALBUQUERQUE, N.M., May 13, 2019 (GLOBE NEWSWIRE) -- The New Mexico Medical Cannabis Program patient revenues from the [...]
Orion Corporation completed share acquisitions
13/05/2019
ORION CORPORATION STOCK EXCHANGE RELEASE 13 MAY 2019 at 18.45 EEST Orion Corporation completed share acquisitions The share acquisitions announced by Orion Corporation on 25 April 2019 have been completed. The Company [...]
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
13/05/2019
ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) reports the following transactions: 1. Details of the person discharging managerial responsibility / person closely associated a) Name Henrik Jacobi 2. Reason for the [...]
ORION CORPORATION: ACQUISITION OF OWN SHARES 13.05.2019
13/05/2019
Orion Corporation NOTIFICATION 13.05.2019 at 18:30 ORION CORPORATION: ACQUISITION OF OWN SHARES 13.05.2019 Date 13.05.2019 Exchange transaction Buy Share class ORNBV Amount 9,906 Average price/share 29.0034 EUR Highest [...]

Pages